NCT05802654尚未招募不适用
Clinical Study of Single Ultra-high Dose Stereotactic Body Radiation Therapy for Early Lung Cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- PFS
研究概览
简要总结
The goal of this prospective single-arm phase II study is to study the efficacy and safety of stereotactic body radiotherapy (SBRT) for early lung cancer. The main questions it aims to answer are:
How effective is this regimen of SBRT for early lung cancer? How safe is this regimen of SBRT for early lung cancer?
详细描述
The goal of this prospective single-arm phase II study is to study the efficacy and safety of stereotactic body radiotherapy (SBRT) for early lung cancer. This study intends to enroll 100 participants in 2 years. The participants enrolled will receive single fraction of ultra-high dose stereotactic body radiotherapy (SBRT) (30Gy/1F).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed written informed consent;
- •Male or female aged ≥ 18 years and ≤ 75 years;
- •patients with early stage lung cancer confirmed by pathology or clinical MDT;
- •The physical state score (ECOG PS) of the eastern tumor cooperative group was 0 ~ 1;
- •Expected survival time ≥3 months;
- •Laboratory results during screening must meet the following requirements:
- •Blood routine: neutrophil absolute count (ANC) ≥ 1.5 × 109/L, platelet count (PLT) ≥ 100 × 109/L, hemoglobin (HGB) ≥ 90 g/L (no blood transfusion or erythropoietin dependence within 7 days);
- •Liver function: total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal value (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were less than 2.5 times ULN in subjects without liver metastasis, and ALT and AST were less than 5 times ULN in subjects with liver metastasis.
- •Renal function: serum creatinine (Cr) ≤1.5 times ULN or Cr clearance ≥60 mL/min (Cockcroft-Gault formula), and urine protein (UPRO) < on routine urine test; 2+ or 24 h urinary protein quantification < 1g;
- •International standardized ratio (INR) ≤1.5 times ULN and partial prothrombin time (PTT) or activated partial thrombin time (APTT) ≤1.5 times ULN during the 7 days prior to treatment;
- •For female subjects of reproductive age, urine or serum pregnancy tests should be negative within 3 days prior to receiving the first fraction of SBRT. If the urine pregnancy test results cannot be confirmed negative, a blood pregnancy test is requested;
- •Compliance with the research protocol is expected to be good.
排除标准
- •currently participating in an interventional clinical trial;
- •any unstable systemic disease, including but not limited to active infection, congestive heart failure [New York Heart Association (NYHA) class ≥ II], severe arrhythmia requiring medical therapy, liver, kidney, or metabolic disease; Type I and type II respiratory failure;
- •other malignancies within 5 years before randomization, except adequately treated cervical carcinoma in situ, basal cell or squamous skin cancer, local prostate cancer after radical surgery, ductal carcinoma in situ after radical surgery, or papillary thyroid cancer;
- •women who are pregnant or breastfeeding or who plan to become pregnant or breastfeeding during the study period;
结局指标
主要结局
PFS
时间窗: 3 years
The time from the date of treatment to the date of disease progression or death or last follow-up.
次要结局
- OS(3 years)
- AE(3 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001)Immune Thrombocytopenia PurpuraNCT01963260Merck Sharp & Dohme LLC50
已完成
1 期
A Study to Examine the Safety and Tolerability of Single Ascending Doses of REGN2477Healthy VolunteersNCT02870400Regeneron Pharmaceuticals41
进行中（未招募）
1 期
A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)Lysosomal Storage DiseasesPompe Disease (Late-onset)Glycogen Storage Disease Type 2Glycogen Storage Disease Type IILOPDAcid Maltase DeficiencyPompe DiseaseNCT04093349Spark Therapeutics, Inc.4
已完成
1 期
Evaluation the Pharmacokinetics,Safety,Tolerability of Single Intravitreal Injection RC28-E in Subjects With Wet Age-Related Macular DegenerationNeovascular Age-related Macular DegenerationNCT03777254RemeGen Co., Ltd.12
已完成
1 期
Single Dose Escalation Study of ONO-9054 in Healthy VolunteersHealthy Adult SubjectsNCT01508988Ono Pharma USA Inc48